iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a report released on Friday,Benzinga reports. They currently have a $46.00 price target on the stock.

ITOS has been the subject of several other research reports. JPMorgan Chase & Co. reduced their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Tuesday, November 12th.

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock opened at $7.88 on Friday. iTeos Therapeutics has a one year low of $7.82 and a one year high of $18.75. The stock’s 50 day moving average price is $10.12 and its 200 day moving average price is $13.98. The firm has a market capitalization of $287.89 million, a PE ratio of -2.50 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. On average, analysts forecast that iTeos Therapeutics will post -3.57 earnings per share for the current fiscal year.

Institutional Trading of iTeos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ITOS. Acadian Asset Management LLC acquired a new stake in iTeos Therapeutics during the 1st quarter worth about $3,337,000. Clearline Capital LP acquired a new stake in shares of iTeos Therapeutics during the 2nd quarter valued at $2,328,000. Candriam S.C.A. purchased a new position in shares of iTeos Therapeutics during the 2nd quarter valued at $7,558,000. Kennedy Capital Management LLC acquired a new position in shares of iTeos Therapeutics in the first quarter worth $1,988,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after acquiring an additional 117,159 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.